Author: Ravi Shankar

TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced financial and operational results for the third quarter of 2026. All financial references are denominated in Canadian dollars unless otherwise noted.

Abaxx delivered a strong third quarter. Average daily trading volume and open interest both reached their highest quarterly levels to date on Abaxx Exchange. Transaction and clearing fees continued to offset liquidity-related credits for building liquidity in its markets, and the Company’s net loss narrowed to $20.4 million in Q3 2026 from $28.8 million in Q2 2026. Net cash spend totaled $16.8 million, up 2.8% from Q2. Excluding approximately $2.0 million in one-time professional fees and costs, net cash spend was $14.8 million, 9.4% below Q2’s reported level. The Company ended the quarter with $68.1 million in cash and cash equivalents and remains in a secure financial position to fund its strategic priorities.

Q3 2026 Summary
Key Commercial Metrics
	Three Months Ended September 30, 2026	Three Months Ended June 30, 2026	% Change QoQ	Six Months Ended September 30, 2026	% Change vs. Prior Six Month Period
Total volume (contracts)	1,522,286	888,902	71%	2,411,188	625%
Average daily volume (contracts)	23,420	14,572	61%	19,136	619%
Average daily open interest	782	641	22%	714	112%

The prior six-month period is October 1, 2025–March 31, 2026

Financial Highlights Amounts in C$000s
	Three Months Ended September 30, 2026	Three Months Ended June 30, 2026
Transaction and clearing fees	7,002	4,496
Liquidity-related credits	(6,994)	(4,495)
Trading and clearing revenue	8	2
Royalty income	81	—
Revenue	89	2

Liquidity and Cash Management Amounts in C$000s
	Three Months Ended September 30, 2026	Three Months Ended June 30, 2026
Net cash spending	16,802	16,346
Cash and cash equivalents	68,062	95,074

Net cash spend is calculated as total operating expenses less share-based compensation, total revenue, investment and interest income, and other income.

Business Highlights

• Gulf of Mexico LNG (GOM), North Pacific Asia LNG (NPA), Gold Singapore (GKS) and Lithium Carbonate Singapore (LCS) futures each reached new quarterly volume highs. Compared with Q2, volume increased 17% for GOM, 19% for NPA, 42% for GKS and 9% for LCS.
• Silver Singapore futures traded more than 454,000 contracts in their first full quarter following the May launch.
• Expanded market data distribution to Bloomberg in July, completing connectivity to Bloomberg and LSEG, alongside existing distribution through Zema Global and TradingView.
• Integrated MarketOS™ applications with AbaxxOne on a shared software architecture designed to accelerate new integrations within Abaxx Exchange and beyond.

Subsequent to Quarter End

• Appointed Dr. Jeff Currie as Non-Executive Chairman of the Board. Josh Crumb continues as Chief Executive Officer.
• Appointed technology and energy veteran Alison Ford as an independent director and named Mark A. Jacobsen Executive Legal Counsel and Head of Global Governance.
• Announced three financially settled LNG futures contracts for launch on November 16, adding currency and contract size options for managing waterborne LNG price risk and expanding the commercial reach of Abaxx’s LNG futures suite.
• Announced Gold Singapore CNH Cash-Settled futures for launch on November 16, extending the reach of Abaxx’s Singapore kilobar gold prices into offshore renminbi markets and supporting their use across major international bullion centers.
• Through October, second-half trading volume reached 2,310,182 contracts, 105% above the first-half total, exceeding the Company’s guidance of 50%–100% half-over-half growth with two months remaining in the year.

Investor Reporting

Beginning with its fourth-quarter 2026 financial results, Abaxx intends to provide initial guidance on net cash usage and milestones toward cash-flow breakeven and introduce additional quarterly operational metrics consistent with those reported by major international exchange operators.

Q3 2026 Earnings and Business Update Call

The Company will host its Q3 2026 Earnings and Business Update webcast today at 8:30 a.m. Eastern Standard Time. Prepared remarks will be followed by a live Q&A session. The webcast is available through the Company’s Investor Relations website at investors.abaxx.tech under “Events.”

This release should be read in conjunction with the Company’s third-quarter 2026 unaudited condensed interim consolidated financial statements and management discussion and analysis for the three and nine months ended September 30, 2026, prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, and which are available on SEDAR+ and the Company’s investor relations website at investors.abaxx.tech.

About Abaxx Technologies
Abaxx Technologies Inc. (TSX: ABXX | OTCQX: ABXXF) is building Smarter Markets: markets empowered by better tools, better benchmarks, and better technology to drive market-based solutions to the biggest challenges we face as a society, including the energy transformation and the transition to an AI-augmented economy.

In addition to developing and deploying financial technologies that make communication, trade, and transactions easier and more secure, Abaxx is the majority shareholder of Abaxx Singapore, the owner of Abaxx Exchange and Abaxx Clearing, parent company of wholly owned subsidiaries Abaxx Spot and Adaptive Infrastructure, and founder and creator of Abaxx Labs and the SmarterMarkets™ podcast.

For more information, visit investors.abaxx.tech, abaxx.exchange, abaxxspot.com and smartermarkets.media

For more information about this press release, please contact:

Steve Fray, CFO
Tel: +1 647-490-1590

Media Inquiries
Tara Hayes
Email: tara@abaxx.tech

Investor Inquiries
Tel: +1 246 271 0082
E-mail: ir@abaxx.tech

Cautionary Statement Regarding Forward-Looking Information

This press release includes certain “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities laws. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “believe”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “may”, “will”, “plan”, “should”, “would”, “could”, “target”, “propose”, “goal”, “objective”, “ongoing”, “potential”, “likely” or the negative thereof or similar expressions.

In particular, this press release contains forward-looking statements including, without limitation, statements regarding Abaxx’s objectives, future plans, development of its market infrastructure and technology, plans to provide quarterly investor guidance, introduction and timing of implementation of new futures contracts, and anticipated benefits and use cases for Abaxx’s futures contracts. Forward- looking statements are based on the reasonable assumptions, estimates, analyses and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Factors that could cause actual results to differ materially include, among others: delays in implementation, or failure to implement some or all of the new futures contracts on the expected timeline or at all; risks relating to the global economic climate; the risk that trading volume, average daily volume, and open interest on Abaxx Exchange may not continue to grow, or may decline, if the liquidity- related credits provided under Abaxx’s market maker and liquidity provider programs are reduced, discontinued, or otherwise changed, or if market participants who currently trade on Abaxx Exchange in connection with such programs do not continue to trade, or do not increase their trading activity, independently of such programs; changes in market conditions, trading activity and participant responses; failure or delays related to the onboarding of clearing members; dilution; Abaxx’s limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the industry; currency exchange risks; the need for Abaxx to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of intellectual property and proprietary rights; the effect of government regulation and compliance on Abaxx and the industry; acquiring and maintaining regulatory approvals for Abaxx’s products and operations; the ability to list Abaxx’s securities on stock exchanges in a timely fashion or at all; the failure of energy, commodity markets and collateral use cases to develop according to the expectations of Abaxx; risks related to operations in foreign jurisdictions; network security risks; the ability of Abaxx to maintain properly working systems; reliance on key personnel; contractual risk; third-party risk; clearinghouse risk; malicious actor risks; third-party software license risk; system failure risk; risk of technological change; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; volatile securities markets impacting security pricing unrelated to operating performance; changes in global weather patterns; changes in the price of commodities, capital market conditions, restrictions on labor and international travel and supply chains, and the risk factors identified in the Company’s most recent management’s discussion and analysis filed on SEDAR+.

In addition, particular assumptions which could impact future results of the business of Abaxx include, but are not limited to, Abaxx’s assumption that: LNG and international and Chinese domestic gold bullion markets develop as planned and are not materially disrupted; it will be able to successfully implement its recently announced governance and disclosure initiatives; it will be able to prepare and disclose quarterly guidance to investors; market conditions will be supportive and participant demand will be sustained; trading volume and liquidity on Abaxx Exchange will continue to develop over time, independently of its market maker and liquidity provider programs; additional clearing members will complete onboarding and begin clearing activities according to Abaxx’s expectations; Abaxx will be able to execute its business plan and growth strategy; Abaxx will retain or successfully replace its key personnel; Abaxx will protect its intellectual property rights; energy and commodity markets will continue to develop according to Abaxx’s expectations; collateral use cases for Abaxx’s products will develop in line with Abaxx’s expectations; the demand for centrally cleared, physically deliverable futures and derivatives will grow as anticipated; regulatory approvals required for Abaxx’s products and operations will remain in good standing or will be obtained as required; applicable laws and regulations will not change in a way that adversely affects Abaxx’s business, and that its technology, systems and infrastructure will operate as intended without significant failure, security breach or disruption; third-party service providers, clearing and settlement partners and other service providers will continue to perform their obligations and act according to Abaxx’s expectations; general economic and capital market conditions, commodity prices, currency exchange rates and the supply chain environment will not deteriorate in a way that materially affects Abaxx or its participants, and that Abaxx’s competitive environment will not change materially. Abaxx has also assumed that no significant events occur outside of Abaxx’s normal course of business.

Abaxx cautions that the foregoing list of material factors, risks and assumptions is not exhaustive. In addition, although Abaxx has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. When relying on forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The forward-looking statements and information contained in this press release represent the expectations of Abaxx as of the date of this press release and, accordingly, are subject to change after such date. Abaxx undertakes no obligation to update or revise any forward- looking statements and information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements and information. Neither the Toronto Stock Exchange nor any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Expected revenue increase comes from existing customer agreements, renewals and broader business activities, including a three-year renewal with a major global streaming platform

In autonomous vehicles, where customers process data at petabyte scale, even a small number of production customers could have a substantial impact on Beamr’s future revenues

Herzliya, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (Nasdaq: BMR), a leader in video optimization technology and solutions, today issued a Letter to Shareholders from Sharon Carmel, Chief Executive Officer.

Dear Shareholders,

The autonomous vehicle (AV) strategy we set out this year is now being actively implemented. The pace of our work picked up sharply in Q3: we launched Beamr Lossless, GPU-accelerated and running in real time in the test vehicle, extending our ML-Safe technology; we brought our solution into the tools AV teams already run, including RTMaps from Intempora, a dSPACE company; and we joined the VAST Cosmos Community as a Technology Partner. We are currently working with 12 AV companies, including Tier-1 suppliers and global AV programs.

AI systems are creating enormous demand for visual data, and video is now one of the largest data types feeding them. Our work with AV teams, managing hundreds of petabytes of video data per program, has confirmed what this costs them: storage and networking are not only expensive, they slow development down. Handling these pipelines efficiently, without compromising the performance of AI, is becoming a fundamental requirement. That is why we built ML-Safe compression.

The scale of the opportunity matters for a company of our size: with customers processing massive datasets, even a relatively small number of production customers can have a substantial impact on our revenues. Our focus now is commercial execution: converting the engagements we have built into production customers.

Revenue growth and longer visibility*

As we published in September, we expect 2026 revenues to increase by about 50% over 2025, to approximately $4.5 million. That growth comes from existing customer agreements, renewals and broader business activities, including a three-year renewal with a major global streaming platform that runs through October 2029.

We believe the multi-year renewal, together with other customer renewals, reflects the continued value and sustainability of our technology, expertise and services. This is a significant change from our customary annual renewals, and it enhances our visibility into our anticipated future revenues while we continue to pursue new growth opportunities.

We sell on usage, per gigabyte and per hour processed. A customer commits little while ramping up and pays more as volumes rise. As AV video data is expanding sharply, once customers increase their usage, our consumption-based pricing creates an opportunity for revenue to grow alongside their video volumes.

Beamr Lossless: savings from capture

Through our joint work with AV and ADAS companies we identified their need for compression in the test vehicle, supporting multiple camera streams in real time. So we built it.

Beamr Lossless compression, GPU-accelerated in real time in the test vehicle, compresses 12-bit footage, the AV camera’s raw output – a format in-vehicle encoders could not handle until now. Our initial tests showed video files were 47% smaller than raw – and what is saved at the point of capture is saved again at every step that follows: on the drives, on the way to the cloud, and in every training run that reads it.

Since the launch, AV teams have shown strong interest in Beamr Lossless.

Built for AV teams, delivered through partners

Partners are central to how we reach the AV market. A team already running a partner’s platform adds our compression as a component rather than an integration project – which means we can deploy our solution faster. Our technology is also available on AWS Marketplace, and we are a member of the AWS ISV Accelerate program.

Sales cycles in this market are long, which is part of why we built Blueprint – a defined plan that helps teams decide how compression fits their own content, models and workflows. With it, we answered the demand for a faster path from evaluation to adoption, while opening a commercial channel for Beamr alongside our technology licensing.

Our content-adaptive compression is available on the RTMaps AI Store from Intempora, a dSPACE company that works with OEMs and Tier-1 autonomous vehicle developers worldwide. It is the first compression technology in the store. In September we demonstrated Beamr Lossless running in real time inside RTMaps, at AutoSens Europe, and at the dSPACE User Conference.

We deepened our work with VAST Data, while joining the VAST Cosmos Community. We first demonstrated together at GTC in March on petabyte-scale AV video data. In September we demonstrated at IBC Show in Amsterdam for our media and entertainment customers and prospects. The demonstration included NVIDIA Video Super Resolution for AI quality enhancement, and our content-adaptive technology to reduce the enhanced video file size by up to 50% – running on the VAST AI Operating System.

A key part of what we offer is evidence. We test ML-Safe compression against the industry-standard models and metrics AV teams already rely on, and publish what we find. This month we published our second study on vision-language models, covering a much broader set of AV footage than the first one published earlier this year. The new study showed that Beamr technology achieves 45.9% smaller video data compared to standard encoding while preserving fidelity.

Financial highlights*

During the nine-month period ended September 30, 2026, we generated approximately $1.38 million in revenue, compared to $1.54 million in the corresponding period of 2025. We continue to expect approximately 50% revenue growth for the full year 2026, reaching approximately $4.5 million. Our balance sheet remains solid, with $5.6 million in cash and deposits as of September 30, 2026.

Our strategy from here

Autonomous vehicles are a fast-growing market, and the same challenges appear wherever machines have to see: humanoids, robotics, and the factories where both will operate. Video is how those systems learn, and the cost of moving, storing and processing it is becoming a limit on how quickly they can learn.

Beamr has always been an infrastructure accelerator, reducing video data to speed transfers and lower costs. As AI infrastructure becomes costlier and scarcer, our GPU-accelerated technology works as a capacity multiplier. Beamr technology delivers approximately 2X effective data capacity and transfer throughput for video-intensive workloads, while preserving the tested AI pipeline outputs.

Part of our work now is making this opportunity better understood. In recent months, I set out our position directly on CNBC’s Microcap Minute, on Bloomberg TV and CNBC through RedChip’s Small Stocks, Big Money, with The Wall Street Transcript and on the Smart Money Circle Podcast.

Our technology is developed, we have established relationships with major players in the industry, and we have created a much simpler path for customers to adopt our solutions. Over the next 12 months, our goal is to translate these activities into commercial agreements and production deployments.

Sincerely,

Sharon Carmel
Chief Executive Officer
Beamr Imaging Ltd.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS).

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to the Company’s expected revenue growth and anticipated full year 2026 revenue; the anticipated benefits of customer agreements and renewals; anticipated revenue visibility; the potential conversion of customer evaluations and engagements into commercial agreements and production deployments; the potential effect of consumption-based pricing and increased customer usage on revenue; and the potential impact of autonomous vehicle customers and other market opportunities on the Company’s future revenues and results. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
investorrelations@beamr.com

*The revenue guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause the Company’s actual results to differ materially from these forward-looking statements, as well as the Company’s Annual Report on 20-F for the fiscal year ended December 31, 2025, including in “Operating and Financial Review and Prospects” and “Risk Factors”, for further context. This financial information has been prepared solely on the basis of currently available information by, and is the responsibility of, management. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to such preliminary estimates or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. This preliminary financial information is not a comprehensive statement of our financial results for this period.

The research describes compelling preclinical findings providing the foundation for a planned Phase II clinical study, currently under review by health authorities in Italy

Ramat Gan, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of research demonstrating that piclidenoson (IB-MECA), an orally administered A3 adenosine receptor agonist, corrects disease-associated cellular abnormalities and improves kidney protein reabsorption in preclinical models of Lowe syndrome. The findings were published in Signal Transduction and Targeted Therapy, a Nature Portfolio journal. https://doi.org/10.1038/s41392-026-03054-z

The study, entitled “An actionable GPCR restores phosphoinositide homeostasis and kidney function in Lowe syndrome,” was led by researchers including Dr. Leopoldo Staiano and Prof. Maria Antonietta De Matteis at the Telethon Institute of Genetics and Medicine (TIGEM), with collaborators at the University of Naples Federico II and other international institutions.

Lowe syndrome is a rare genetic disorder affecting the eyes, brain and kidneys, for which no curative therapy is currently available. Its kidney manifestations include impaired protein reabsorption, urinary protein loss and progressive kidney disease.

The researchers identified piclidenoson through screening of 1,280 compounds and demonstrated its activity across multiple experimental systems, including patient-derived kidney cells, human kidney organoids and a humanized mouse model. Piclidenoson restored cellular protein trafficking and protein reabsorption. In the mouse model, five months of treatment reduced urinary levels of a marker of low-molecular-weight proteinuria by 48–80% compared with untreated disease-model mice.

The study also identified the underlying mechanism: activation of the A3 adenosine receptor stimulates phospholipase C, correcting the abnormal accumulation of a membrane lipid that disrupts kidney cell function in Lowe syndrome.

“These findings demonstrate the potential of piclidenoson to address a fundamental cellular defect underlying kidney dysfunction in Lowe syndrome. The consistent activity across patient-derived cells, human kidney organoids and an animal model provides a compelling scientific foundation for advancing its clinical evaluation in this rare disease, said Prof. Pnina Fishman, Can-Fite CSO and Chairperson”.

A Phase II clinical study has been designed and is under review by Italian Health Authorities. The proposed Phase II study is an open-label, single-center clinical trial designed to evaluate the efficacy and safety of oral Piclidenoson administered twice daily for six months in 5 adult patients with genetically confirmed Lowe syndrome. The primary endpoint is improvement in renal uptake of 99mTc-DMSA as a measure of proximal tubular reabsorption capacity, with secondary endpoints.

About Piclidenoson

Piclidenoson is a robust anti-inflammatory agent, currently being evaluated in a pivotal Phase 3 psoriasis clinical study under approval of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II and Phase III clinical studies. The drug’s mechanism of action entails inhibition of the inflammatory cytokines interleukin 17 and 23 (IL-17 and IL-23) and the induction of apoptosis of patients’ skin cell keratinocytes involved with the disease pathogenicity.

About Fondazione Telethon

Fondazione Telethon ETS is one of the main Italian biomedical charities, founded in 1990 on the initiative of a group of patients suffering from muscular dystrophy. Its mission is to achieve the cure of rare genetic diseases through scientific research of excellence, selected according to the best practices shared internationally. Through a unique method in the Italian panorama, it follows the entire “research chain” dealing with fundraising, selection and funding of projects and the research activity itself carried out in the centers and laboratories of the Foundation. Telethon also develops collaborations with public health institutions and pharmaceutical industries to translate the results of research into therapies accessible to patients.  Since its foundation, Telethon has invested more than 660 million euros in research, has funded 2,960 projects with 1,720 researchers involved and 630 diseases studied. To date, thanks to Fondazione Telethon, the first gene therapy with stem cells in the world has been made available, thanks to the collaboration with the pharmaceutical industry. This therapy is intended for the treatment of ADA-SCID, a severe immunodeficiency that compromises the body’s defenses from birth. In 2023, Fondazione Telethon became responsible for the production and distribution of the drug to eligible patients in the European Union 

Another gene therapy resulting from Telethon research made available is the one for a serious neurodegenerative disease, metachromatic leukodystrophy. This therapeutic approach is in an advanced stage of development for another immunodeficiency, Wiskott-Aldrich syndrome. Other diseases on which the gene therapy developed by Telethon researchers has been evaluated in patients are beta thalassemia and two metabolic diseases of childhood, mucopolysaccharidosis type 6 and type 1. In addition, within the Telethon institutes a targeted therapeutic strategy is being studied or developed for other genetic diseases, such as hemophilia or various hereditary vision defects. In parallel, the study of basic mechanisms and potential therapeutic approaches for diseases still unanswered continues in all laboratories funded by Telethon. 

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,700 patients in clinical studies to date. For more information please visit: www.canfite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts of Piclidenoson for the treatment of Lowe syndrome including the timing and outcome of regulatory review of the planned Phase II study in Lowe syndrome, Can-Fite’s ability to initiate and enroll patients in such study, and the results of any such study. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contact

Can-Fite BioPharma

Motti Farbstein

 info@canfite.com

+972-3-9241114

• Total revenue of $415 million, an increase of 6% year over year and 6% on an Organic Constant Currency basis
• Recurring revenue of $291 million, an increase of 5% year over year and 5% on an Organic Constant Currency basis
• Annualized recurring revenue (“ARR”) of $1,171 million, an increase of 7% year over year
• Cash flow from operations of $95 million and Free cash flow of $65 million

HUNTSVILLE, Ala., Nov. 12, 2026 (GLOBE NEWSWIRE) —  Octave Intelligence plc (Nasdaq New York: OCTV and Nasdaq Stockholm: OCTV SDB) today announced financial results for the third quarter of 2026, ended September 30, 2026.

“Our third quarter results were in line with our expectations, and we remain on track to achieve our outlook for the full year. ARR grew 7% over the prior year to $1.17 billion, and SaaS revenue grew 18%, as we continue our focused shift toward recurring revenue. Product innovation and go-to-market improvements continued to gain traction this quarter, and we’re carrying that momentum into the fourth quarter,” said CEO Mattias Stenberg. 

“Additionally, our Board of Directors recently approved a $200 million share repurchase program, a decision that reflects its confidence in our company strategy, medium-term financial targets, and ability to grow free cash flow.”

Third Quarter 2026 Financial Highlights and Key Business Metrics:

USD millions, except EPS and percentages		Q3 2026		Q3 2025
Total revenue		$415		$393
Annualized recurring revenue (ARR)		$1,171		$1,090
Income (loss) from operations		$56		$33
Operating margin		13%		8%
Adjusted income from operations		$116		$106
Adjusted operating margin		28%		27%
Net income (loss)		$59		$14
Adjusted net income		$86		$87
Earnings per share		$0.22		$0.05
Adjusted earnings per share		$0.32		$0.32
Cash flow from operations		$95		$102
Cash flow from operations margin		23%		26%
Free cash flow		$65		$64
Free cash flow margin		16%		16%

Recent Business Highlights

• In November, Octave announced the acquisition of Cerebre, a U.S.-based software company that transforms fragmented engineering schematics, plant data and engineering knowledge into a connected plant model. Combining Octave’s engineering record and Cerebre’s plant model will strengthen industrial AI use cases and has high-growth potential in brownfield facilities where plant data remains largely disconnected. 
• In November, Octave announced the launch of Attune Facilities, a cloud-based facilities management solution for organizations managing multiple sites. Octave Attune Facilities includes AI tools to help facilities teams operate more efficiently across complex, multi-site environments.
• In October, Octave released a new version of Alto, the company’s geospatial solution that powers 2D / 3D / 4D visualization, analytics, data fusion, digital twins and real-time operations. The latest release brings live drone and camera video directly onto 2D maps and 3D terrain, so operators not only see what a camera sees but can also access all the critical geospatial information attached to that camera’s view.
• In October, Octave was the only company named a Leader in both the ARC Advisory Group’s MarketMap for Enterprise Asset Management and the MarketMap for Digital Worker Technologies for Manufacturing. ARC also classified Octave as a Transformation Pioneer in Enterprise Asset Management (EAM).
• In September, Octave released a new research report on industrial workforce trends. The report surveyed more than 750 industrial leaders and found that widespread retirements and workforce shortages continue to present challenges to fill key roles and capture legacy expertise, all while AI is reshaping what the future workforce will look like, and the skills needed to succeed.

Share Repurchase

Octave today announced that its Board of Directors has approved a share repurchase program covering purchases of its Octave Class B Ordinary Shares, which are listed on the Nasdaq Global Select Market, and Swedish Depository Receipts for its Octave Class B Ordinary Shares (“Octave SDRs”), which are listed on Nasdaq Stockholm (the “Program”).

The principal terms of the Program are:

• The purpose of the Program is to offset dilution resulting from equity-based compensation and provide flexibility for additional repurchases as part of Octave’s capital-allocation strategy.
• Purchases may be made from and including November 13, 2026, and continue through the end of 2029, unless the Program is completed or terminated earlier in accordance with applicable law.
• Octave may acquire up to 10,750,000 Octave Class B Ordinary Share equivalents, consisting of Octave Class B Ordinary Shares purchased directly and/or Octave SDRs, with each SDR counting as one Octave Class B Ordinary Share equivalent, for aggregate consideration of up to $200,000,000. Purchases in both markets together may not exceed either aggregate limit.
• Octave Class B Ordinary Shares may be acquired in open-market or privately negotiated transactions or by other means as permitted by applicable securities laws. Octave SDRs may be acquired on Nasdaq Stockholm in accordance with Nasdaq Stockholm’s Rule Book for Issuers on the Main Market and with observance of its price limitations set out therein. All purchases will be made in cash.

The timing, amount and allocation of purchases between the two markets will depend on market conditions, applicable legal requirements and other considerations. The Program does not require Octave to acquire the full authorized amount. Any suspension, modification or termination may be undertaken in Octave’s discretion, subject to applicable law.

As of the date hereof, Octave holds zero Class A Ordinary Shares and zero Octave Class B Ordinary Shares as treasury shares and holds zero Octave SDRs. Octave has 11,025,000 Class A Ordinary Shares and 257,412,788 Octave Class B Ordinary Shares issued, of which a portion are represented by Octave SDRs.

Fourth Quarter and Full Year 2026 Guidance

Octave is providing fourth quarter guidance and its full year 2026 outlook, including expectations for certain key business metrics as set out below.

USD millions, except percentages

		Q4 2026		Full Year 2026
Total revenue		$440 – $460		$1,640 – $1,660
Annualized recurring revenue (ARR)		N/A		$1,185 – $1,205
Total revenue growth y/y (organic, constant currency)		(2) – 2%		0.5 – 2%
ARR growth y/y (organic, constant currency)		N/A		6 – 8%
Recurring revenue		$292 – $297		$1,145 – $1,150
Recurring revenue growth y/y (organic, constant currency)		5 – 6%		5.5 – 6%
Adjusted Operating Margin		31 – 32%		~30%
Free Cash Flow Margin		N/A		~20%

Reconciliations of the forecasts of Adjusted operating margin, Free cash flow margin, and organic constant currency growth to the most directly comparable U.S. GAAP measures have not been provided because they cannot be prepared without unreasonable effort. See the section entitled “Explanation of Non-GAAP Financial Measures” and the reconciliation of GAAP measures to non-GAAP measures at the end of this release. Assumptions underlying our guidance include continued customer retention consistent with historical experience, successful execution of cross-selling and upselling initiatives, ongoing SaaS adoption (including the migration of certain maintenance and license-based offerings), and no material adverse changes in macroeconomic conditions or end-market demand. See “Forward-Looking Statements” for additional assumptions.

Conference Call Information

Octave will host a conference call today, November 12, 2026, to discuss its results at 8:00 a.m. Eastern time. The call will be available live via webcast on Octave’s website at https://investors.octave.com. A webcast replay of the event will also be available at https://investors.octave.com. 

Date: November 12, 2026
Time: 8:00 a.m. ET; 14:00 CET

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact, including, without limitation, statements regarding our financial guidance, expected revenue, annualized recurring revenue, recurring revenue, Adjusted operating margin, Adjusted net income per share, weighted average shares outstanding, Free Cash Flow margin, free cash flow, future financial position, results of operations, business strategy, budgets, projected costs, the timing, amount, funding and expected benefits of repurchases under our share repurchase program, the integration of Cerebre and the expected financial, operational, technical, and other benefits of the acquisition, plans and objectives of management for future operations, are forward-looking statements. Use of words such as “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “anticipates,” “continues,” “forecasts,” “target,” “outlook,” “objective,” “goal” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Forward-looking statements are based on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives and financial needs, and on a number of assumptions. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, among other things, customer demand for our software solutions, subscription license activity, SaaS adoption, pricing and packaging initiatives, macroeconomic conditions, our ability to identify, consummate and successfully integrate strategic acquisitions, our ability to successfully operate as an independent public company following the spin-off from Hexagon, the timing and costs associated with separation-related activities, our ability to generate sufficient cash flows and comply with the terms of our indebtedness, our ability to execute our growth strategies, and other risks and uncertainties included under the section titled “Risk Factors” in the Information Statement attached as Exhibit 99.1 to Octave’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2026 available on our investor relations website at investors.octave.com and on the SEC website at www.sec.gov. Additional information regarding these risks and uncertainties will also be set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including under “Risk Factors,” and in other documents we file with the SEC. All information provided in this press release and in the attachments is as of November 12, 2026. You should not rely upon forward‑looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward‑looking statements will be achieved or occur, including any expected or targeted financial or operating results. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward‑looking statements. Except as required by law, we undertake no obligation to update publicly any forward‑looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

Investor Relations Contact

Elizabeth Chwalk, VP, Investor Relations, elizabeth.chwalk@octave.com 
investors@octave.com 

This information is information that Octave Intelligence plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on 12 November 2026.

Media: media@octave.com 

OCTAVE INTELLIGENCE PLC Condensed Consolidated Balance Sheets (Unaudited) In thousands (except per share amounts)
	As of
	September 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	296,993			$	156,069
Accounts receivable, net	366,935				400,686
Prepaids and other current assets	93,727				100,008
Total current assets	757,655				656,763
Property and equipment, net	23,213				54,642
Operating lease right-of-use assets	54,237				50,605
Goodwill	4,553,153				6,221,366
Intangible assets, net	1,144,226				1,649,408
Deferred income taxes	23,620				29,903
Other noncurrent assets	45,531				33,564
Total assets	$	6,601,635			$	8,696,251
LIABILITIES
Current liabilities:
Accounts payable	$	48,704			$	48,765
Accrued compensation	99,300				113,532
Deferred revenue	419,913				380,612
Operating lease liabilities	15,512				15,683
Other current liabilities	123,056				94,282
Total current liabilities	706,485				652,874
Long-term debt	518,477				—
Operating lease liabilities – noncurrent	40,665				36,770
Deferred income taxes	151,073				269,152
Other noncurrent liabilities	37,963				59,820
Total liabilities	1,454,663				1,018,616
EQUITY
Preferred shares, $0.01 par value; 1,000,000 shares authorized; no shares issued	—				—
Class A Ordinary Shares, $0.01 par value; 4,500,000 shares authorized	110				—
Class B Ordinary Shares, $0.01 par value; 4,500,000 shares authorized	2,574				—
Additional paid-in-capital	6,791,452				—
Net investment by Hexagon	—				7,749,558
Retained earnings	(1,570,916		)		—
Accumulated other comprehensive loss	(76,248		)		(71,923		)
Total equity	5,146,972				7,677,635
Total liabilities and equity	$	6,601,635			$	8,696,251

OCTAVE INTELLIGENCE PLC Condensed Consolidated Statements of Operations (Unaudited) In thousands (except per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenue:
Subscription licenses	$	74,486			$	70,457			$	219,397			$	218,271
SaaS	91,431				77,636				263,325				216,484
Maintenance subscription	124,672				127,982				369,860				367,486
Subscriptions	290,589				276,075				852,582				802,241
Licenses	34,060				35,362				108,289				128,984
Subscriptions and licenses	324,649				311,437				960,871				931,225
Services and other	90,673				81,874				239,366				258,231
Total revenue	415,322				393,311				1,200,237				1,189,456
Cost of revenue:
Cost of subscriptions and licenses	37,176				45,718				120,942				126,926
Cost of services and other	64,829				52,258				162,649				177,526
Total cost of revenue	102,005				97,976				283,591				304,452
Gross profit	313,317				295,335				916,646				885,004
Operating expenses:
Research and development	56,228				46,423				158,292				136,267
Sales and marketing	103,240				100,900				299,733				287,441
General and administrative	45,355				44,813				127,416				124,672
Amortization of intangible assets	48,337				39,642				135,900				115,279
Other operating expense (income), net	4,144				30,953				2,145,583				17,977
Total operating expenses	257,304				262,731				2,866,924				681,636
Income (loss) from operations	56,013				32,604				(1,950,278		)		203,368
Other income (expense), net	22,651				(16,049		)		26,753				(15,838		)
Interest expense, net	(5,071		)		—				(6,828		)		—
Income (loss) before income tax	73,593				16,555				(1,930,353		)		187,530
Provision (benefit) for income taxes	14,581				2,418				(66,068		)		38,739
Net income (loss)	$	59,012			$	14,137			$	(1,864,285	)		$	148,791
Earnings per share
Basic	$	0.22			$	0.05			$	(6.94	)		$	0.55
Diluted	$	0.22			$	0.05			$	(6.94	)		$	0.55
Weighted average ordinary shares outstanding
Basic	268,438				268,438				268,438				268,438
Diluted	268,477				268,438				268,438				268,438

OCTAVE INTELLIGENCE PLC Condensed Consolidated Statements of Cash Flows (Unaudited) In thousands
	Nine Months Ended September 30,
	2026				2025
Cash flows from operating activities:
Net income (loss)	$	(1,864,285	)		$	148,791
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	144,172				124,308
Stock-based compensation expense	14,230				12,286
Deferred income taxes	(89,548		)		(2,533		)
Impairment charges	2,134,660				—
Remeasurement of contingent consideration reserves	(2,622		)		(23,535		)
Loss on divestitures, net	—				16,578
Gain on sale of buildings	(25,946		)		—
Restructuring charges	(10,687		)		33,195
Other	607				1,610
Changes in assets and liabilities, net of effect from acquisitions:
Accounts receivable	31,340				17,728
Prepaids and other current assets	4,131				(4,314		)
Accounts payable	(2,076		)		(4,745		)
Accrued compensation	(14,232		)		(3,869		)
Deferred revenue	14,165				17,490
Other assets and liabilities	2,346				17,539
Net cash provided by operating activities	336,255				350,529
Cash flows from investing activities:
Purchases of property and equipment	(7,468		)		(6,087		)
Capitalization of software development costs	(88,309		)		(101,810		)
Acquisitions, net of cash acquired	(11,115		)		(16,751		)
Purchases of investments	(15,000		)		—
Proceeds from divestitures	—				57,049
Proceeds from sale of buildings	57,250				—
Other	(3,985		)		(3,051		)
Net cash used in investing activities	(68,627		)		(70,650		)
Cash flows from financing activities:
Proceeds from issuance of term loans	524,420				—
Proceeds from revolving credit facility	149,070				—
Repayment of revolving credit facility	(148,944		)		—
Debt issuance costs	(3,779		)		—
Net transfers to Hexagon	(16,048		)		(273,854		)
Cash payment to Hexagon in connection with the Distribution	(625,000		)		—
Payment of contingent consideration	(606		)		—
Proceeds from other short-term borrowings	22,903				—
Repayments of other short-term borrowings	(23,071		)		—
Net cash used in financing activities	(121,055		)		(273,854		)
Effect of foreign exchange rate changes on cash and cash equivalents	(5,649		)		5,886
Net increase in cash and cash equivalents	140,924				11,911
Cash and cash equivalents at beginning of period	156,069				97,214
Cash and cash equivalents at end of period	$	296,993			$	109,125
Supplemental cash flow information:
Income taxes paid, net of refunds	$	23,711			$	7,979
Interest paid	$	6,989			$	—

DEFINITIONS OF KEY BUSINESS METRICS

We believe the presentation of key business metrics provides incremental useful information to investors regarding our results of operations. To the extent material, we disclose below the additional purposes, if any, for which our management uses these key business metrics. Our key business metrics may vary significantly from period-to-period for reasons unrelated to our operating performance and may differ from similarly titled measures presented by other companies. These metrics are based on management calculations derived from available operational data.

Recurring revenue includes monthly subscription licenses, SaaS-based subscriptions and maintenance subscriptions.

Annualized Recurring Revenue (“ARR”) is a key business metric we use to evaluate the scale and growth of our business as well as to assist in the evaluation of underlying trends in our business. ARR represents the annualized value of recurring revenue from our subscription licenses, SaaS-based subscriptions and maintenance subscriptions. It excludes revenue from perpetual software licenses, non-recurring services and other revenues. The Company calculates ARR as the sum of: (i) the annualized value of monthly recurring revenue recognized from SaaS-based subscriptions and maintenance subscriptions in the last month of the most recently completed quarter, plus (ii) the annualized value of recurring revenue recognized from subscription licenses in the most recently completed quarter.

EXPLANATION OF NON-GAAP FINANCIAL MEASURES

Below are definitions and reconciliations of certain non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP. Management believes that, when considered together with reported amounts, these measures are useful to investors and management in understanding our ongoing operations and in the analysis of ongoing operating trends. Management believes these non-GAAP financial measures provide investors with a more meaningful measure of company performance period-to-period, align the measures to how management evaluates performance internally, and make it easier for investors to compare our performance to peers. These measures should be considered in addition to, and not as replacements for, the most directly comparable U.S. GAAP measure. The non-GAAP financial measures we use are as follows:

Adjusted Income from Operations—Income (Loss) from Operations

Adjusted income from operations is defined as Income (loss) from operations adjusted for amortization of acquired intangibles; amortization of developed technologies; stock-based compensation expense; impairment charges; acquisition costs and charges; restructuring charges; stand-up costs; and select other non-recurring items.

Adjusted Operating Margin—Operating Margin

Adjusted operating margin is defined as Adjusted income from operations divided by revenue.

Adjusted Net Income—Net Income (Loss)

Adjusted net income is defined as Net income (loss) adjusted for amortization of acquired intangibles; amortization of developed technologies; stock-based compensation expense; impairment charges; acquisition costs and charges; restructuring charges; stand-up costs; select other non-recurring items; and a corresponding adjustment to income tax expense for the impact of these adjustments.

Adjusted Earnings per share—Earnings per share

Adjusted earnings per share is defined as Adjusted net income divided by the weighted-average number of ordinary shares outstanding during the period, presented on a diluted basis.

Free Cash Flow—Cash Flow from Operations

Free cash flow is defined as cash flow from operations net of capital expenditures, including purchases of property and equipment and capitalization of software development costs. These expenditures consist primarily of facility improvements, office equipment, computer equipment, and software development costs. We believe that free cash flow, in conjunction with cash from operations, is a useful measure of liquidity since capital expenditures are a necessary component of ongoing operations. Free cash flow is not a measure of cash available for discretionary expenditures.

Free Cash Flow Margin—Cash Flow from Operations Margin

Free cash flow margin is defined as free cash flow divided by revenue.

Description of Adjustments

Amortization of acquired intangibles and amortization of developed technologies are non-cash expenses that are impacted by the timing and magnitude of our acquisitions and additions to developed technologies. We believe the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Stock-based compensation expense is a non-cash expense relating to equity-based awards issued to executive officers, employees and outside directors, including restricted share units and performance share units. We believe the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Impairment charges are non-cash expenses related to long-lived assets for which it was determined the carrying value of such assets was partially or fully unrecoverable. We believe the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Acquisition costs and charges are direct costs of potential and completed acquisitions and expenses related to acquisition integration activities, including transaction fees, due diligence costs, severance and professional fees. Subsequent adjustments to our initial estimated amount of contingent consideration associated with specific acquisitions are also included within acquisition costs and charges. The occurrence and amount of these costs and charges varies depending on the timing and size of acquisitions and subsequent adjustments to our initial estimated amount of contingent consideration. We believe the assessment of our operations excluding these costs and charges is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Restructuring charges include excess facility restructuring costs; impairment and accretion expenses related to the lease assets of exited facilities; sublease income from previously impaired facilities; severance charges resulting from employee reduction actions; and third-party professional consulting fees related to modifications of our business strategy. These charges vary in size based on restructuring plans and duration. We believe the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Stand-up costs include expenses associated with the Distribution and stand-up of functions required to operate as a standalone public entity. These costs primarily relate to system implementation expenses, legal and consulting costs, development of our brand and other matters. We believe the assessment of our operations excluding these costs is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Other non-recurring items include selected gains, costs and charges that do not naturally conform to one of the adjustments above, including the gain on the sale of our corporate headquarters, losses on divestitures of non-core businesses and certain litigation matters net of expected insurance recoveries. We believe the assessment of our operations excluding these gains, costs and charges is relevant to our assessment of internal operations and comparisons to the performance of other companies in our industry.

Income tax adjustments include the tax impact of the items excluded from Adjusted net income, which is calculated by applying the statutory tax rates in the respective jurisdictions to each of the pre-tax transaction accounting adjustments.

We use these non-GAAP financial measures, and we believe that they assist our investors, to make period-to-period comparisons of our operational performance because they provide a view of our operating results and cash flows without items that are not, in our view, indicative of our core operating results. We believe that these non-GAAP financial measures, when used in conjunction with the most comparable U.S. GAAP measure, help illustrate underlying trends in our business, and we use the measures to establish budgets and operational goals (communicated internally and externally) for managing our business and evaluating our performance. We believe that providing non-GAAP financial measures also affords investors a view of our operating results and cash flows that may be more easily compared to the results of other companies in our industry that use similar financial measures to supplement their U.S. GAAP results.

The items excluded from the non-GAAP financial measures often have a material impact on our financial results, certain of those items are non-recurring, and other such items often recur. Accordingly, the non-GAAP financial measures included herein should be considered in addition to, and not as a substitute for or superior to, the comparable measures prepared in accordance with U.S. GAAP. The following tables reconcile each of these non-GAAP financial measures to its most closely comparable U.S. GAAP measure on our financial statements.

Guidance for adjusted financial measures excludes amortization of acquired intangibles, amortization of developed technologies, stock-based compensation expense, impairment charges, acquisition costs and charges, restructuring charges, stand-up costs, other non-recurring items and related tax impacts.

Octave has not provided forecasts of the most directly comparable U.S. GAAP measures because certain items required to calculate those U.S. GAAP measures cannot be reasonably predicted without unreasonable effort. With respect to Adjusted operating margin, the Company is unable to reasonably predict future impairment charges, restructuring charges, acquisition costs and charges, stand-up costs, and other non-recurring items without unreasonable effort. With respect to Free cash flow margin, the Company is unable to reasonably predict future operating cash flows without unreasonable effort. With respect to organic constant currency growth, the Company is unable to reasonably predict the future foreign exchange rates and the revenue contribution of acquisitions and divestitures without unreasonable effort. Accordingly, reconciliations of the forecasts of Adjusted operating margin,  Free cash flow margin, and organic constant currency growth to the most directly comparable U.S. GAAP measures have not been provided. The excluded items are uncertain, depend on various factors, and could have a material impact on the corresponding measures calculated in accordance with U.S. GAAP.

NON-GAAP FINANCIAL MEASURES
	Three Months Ended September 30,										Nine Months Ended September 30,
	2026					2025					2026				2025
Income (loss) from operations	$	56,013				$	32,604				$	(1,950,278	)		$	203,368
Amortization of acquired intangibles	20,598					18,814					57,385				55,702
Amortization of developed technologies	28,035					21,113					79,392				60,433
Stock-based compensation expense	7,527					5,484					14,230				12,286
Impairment charges	—					—					2,134,660				—
Acquisition costs and charges	—					(10,991		)			(2,472		)		(23,535		)
Restructuring charges	419					38,843					5,771				42,883
Stand-up costs	3,121					285					5,625				641
Other non-recurring items	—					—					3,000				—
Adjusted income from operations	$	115,713				$	106,152				$	347,313			$	351,778
Operating margin		13	%				8	%				(162)	%			17	%
Amortization of acquired intangibles	5					6					5				5
Amortization of developed technologies	7					5					7				5
Stock-based compensation expense	2					1					1				1
Impairment charges	—					—					178				—
Acquisition costs and charges	—					(3		)			—				(2		)
Restructuring charges	—					10					—				4
Stand-up costs	1					—					—				—
Other non-recurring items	—					—					—				—
Adjusted operating margin		28	%				27	%				29	%			30	%
Net income (loss)	$	59,012				$	14,137				$	(1,864,285	)		$	148,791
Amortization of acquired intangibles	20,598					18,814					57,385				55,702
Amortization of developed technologies	28,035					21,113					79,392				60,433
Stock-based compensation expense	7,527					5,484					14,230				12,286
Impairment charges	—					—					2,134,660				—
Acquisition costs and charges	—					(10,991		)			(2,472		)		(23,535		)
Restructuring charges	419					38,843					5,771				42,883
Stand-up costs	3,121					285					5,625				641
Gain on sale of buildings	(25,946		)			—					(25,946		)		—
Other non-recurring items	—					16,243					3,000				16,578
Tax impacts	(7,205		)			(17,379		)			(137,367		)		(35,353		)
Adjusted net income	$	85,561				$	86,549				$	269,993			$	278,426
Earnings per share – diluted	$	0.22				$	0.05				$	(6.94)			$	0.55
Adjustments	0.10					0.27					7.95				0.48
Adjusted earnings per share – diluted	$	0.32				$	0.32				$	1.01			$	1.04
Weighted average ordinary shares outstanding – diluted	268,477					268,438					268,450				268,438
Cash flow from operations	$	95,377				$	102,011				$	336,255			$	350,529
Purchases of property and equipment	(2,373		)			(2,547		)			(7,468		)		(6,087		)
Capitalization of software development costs	(28,038		)			(35,367		)			(88,309		)		(101,810		)
Free cash flow	$	64,966				$	64,097				$	240,478			$	242,632
Operating cash flow margin	23		%			26		%			28		%		29		%
Purchases of property and equipment	(1		)			(1		)			(1		)		(1		)
Capitalization of software development costs	(6		)			(9		)			(7		)		(8		)
Free cash flow margin	16		%			16		%			20		%		20		%

Constant Currency

Constant currency is a non-GAAP financial measure that presents our revenue excluding the estimated effects of foreign currency exchange rate fluctuations. A significant amount of our operations is conducted in foreign currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We use constant currency to evaluate the underlying performance of the business, and we believe it is helpful for investors to present operating results on a comparable basis period-over-period to evaluate our underlying performance.

In reporting period-over-period results, we calculate the effects of foreign currency fluctuations and constant currency information by translating current and prior period results on a functional currency basis to our reporting currency using the prior period average foreign currency exchange rates from which the transaction occurred.

Reconciliation of revenue to revenue in constant currency for the three and nine months ended September 30, 2026:

	Three Months Ended September 30, 2026																Nine Months Ended September 30, 2026
	Actual			Impact of Foreign Exchange at 2025 Rates				Constant Currency			% as Reported			Organic % CC growth			Actual			Impact of Foreign Exchange at 2025 Rates			Constant Currency			% as Reported			Organic % CC growth
Revenue:
Subscriptions	$	290,589		$	(650	)		$	291,239		5	%		5	%		$	852,582		$	10,897		$	841,685		6	%		6	%
Licenses	34,060			(266		)		34,326			(4)	%		(3)	%		108,289			2,147			106,142			(16)	%		(17)	%
Subscriptions and licenses	324,649			(916		)		325,565			4	%		4	%		960,871			13,044			947,827			3	%		3	%
Services and other	90,673			4				90,669			11	%		10	%		239,366			4,100			235,266			(7)	%		(1)	%
Total revenue	$	415,322		$	(912	)		$	416,234		6	%		6	%		$	1,200,237		$	17,144		$	1,183,093		1	%		2	%

Organic Constant Currency Growth—Revenue Growth

Organic Constant Currency growth presents period-over-period revenue growth excluding both the estimated effects of foreign currency exchange rate fluctuations (as described under Constant Currency above) and the impact of revenue attributable to businesses acquired or divested during the current or comparative period. We believe Organic Constant Currency growth is useful to investors because it presents revenue growth from our existing operations on a comparable basis period-over-period.

Växjö, Sweden, November 12, 2026 * * * JLT Mobile Computers announces changes to its management team to strengthen the company’s commercial focus and local coordination in Växjö.

Christian Funk is appointed Commercial Director, effective immediately. His mandate is to align sales and marketing to drive growth in OEM and new customer acquisition in priority verticals. In his new role, Christian leads the sales team for EMEA and APAC as well as the Global Marketing Manager.

Hannes Beckerin is appointed Site Manager in Växjö, in addition to his role as Director of Global Operations, JLT Group. This appointment strengthens local coordination and gives the CEO more time to focus on customers and business development.

Tejal Ranjan has left her position as global VP of Marketing. The company thanks her for her contributions and wishes her success in her future endeavors.

For more information about JLT Mobile Computers and its computer products, services, and solutions, visit jltmobile.com. Additional financial information is available on JLT’s investor relations pages.

Reader enquiries	Press contact	Certified Adviser
Per Holmberg, CEO	pressrelease@pr.jltmobile.com	Eminova Fondkommission AB
JLT Mobile Computers Group		Tel.: +46 08 684 211 10
Tel.: +46 70 361 3934		adviser@eminova.se
per.holmberg@jltmobile.com www.jltmobile.com		www.eminova.se

About JLT Mobile Computers

JLT Mobile Computers is a leading developer and supplier of rugged mobile computers and solutions for the toughest environments. 30 years of experience have enabled JLT to set the standard in rugged computing through a combination of outstanding product quality, exceptional service and support, and world-class solutions that ensure trouble-free operations for customers in warehousing and logistics, transportation, manufacturing, mining, ports and agriculture. JLT operates globally with offices in Sweden, France and the US and an international network of resellers in local markets. The company was founded in 1994 and has been listed on Nasdaq First North Growth Market since 2002 under the symbol JLT, with Eminova Fondkommission AB as Certified Adviser. For more information, visit jltmobile.com.

Revenue of €62.6 million (+31%), Adj. EBITDA of €4.2 million (+45%), and Gaming Win of €67.1 million (+30%) in the quarter

• Total revenue was €62.6 mm in Q3 2026 (+31%): Spain €24.8 mm (+13%) and Mexico €32.9 mm (+37%).
• Adj. EBITDA reached €4.2 mm in Q3 2026, 45% (€1.3 mm) above Q3 2025.
• Net income was €11.1 mm in 9M 2026, versus a net loss of €1.7 mm in 9M 2025.
• Gaming Win¹ was €67.1 mm in Q3 2026 (+30%): Spain €24.8 mm (+13%) and Mexico €37.2 mm (+39%).
• Total cash position of €65.6 mm and no financial debt as of September 30, 2026.
• Reiterating FY 2026 outlook of €255-265 mm of Gaming Win and €20-25 mm of Adj. EBITDA².

Madrid, Spain and Tel Aviv, Israel, November 12, 2026 – (GLOBE NEWSWIRE) Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW, the “Company” or “Codere Online”), a leading online gaming operator in Spain and Latin America, has released its preliminary unaudited³ financial results for the quarter ended September 30, 2026. Below are the main financial and operating metrics of the period.

	Quarter ended September 30				Nine months ended September 30
	2025	2026	Chg. %		2025	2026	Chg. %
Revenue (EUR mm)
Spain	22.0	24.8	13%		66.1	77.9	18%
Mexico	24.0	32.9	37%		77.8	95.1	22%
Other	1.6	4.9	n.m.		9.4	14.3	52%
Total	47.7	62.6	31%		153.3	187.3	22%
Avg. Monthly Active Players (000s)
Spain	50.2	52.8	5%		50.4	55.4	10%
Mexico	88.3	85.6	(3%)		85.3	90.7	6%
Other	20.7	28.4	37%		22.6	28.4	26%
Total	159.2	166.8	5%		158.3	174.4	10%
Gaming Win (EUR mm)
Spain	22.0	24.8	13%		66.1	77.9	18%
Mexico	26.8	37.2	39%		86.3	107.8	25%
Other	2.8	5.2	86%		11.0	15.3	39%
Total	51.6	67.1	30%		163.4	201.0	23%

Aviv Sher, Chief Executive Officer of Codere Online, commented, “Q3 was another quarter of strong growth, with Gaming Win up 30% year-on-year, driven mainly by Mexico, up 39%, and continued growth in Spain. During the quarter we also became Official Betting Partner of the NFL in Mexico, which further strengthens our positioning in one of our most important markets.”

Marcus Arildsson, CFO of Codere Online, commented, “We delivered €62.6 million of revenue and Adjusted EBITDA of €4.2 million in the quarter, as well as €67.1 million of Gaming Win, while continuing to invest behind growth. We closed September with approximately €66 million of total cash and no financial debt.”

Mr. Arildsson further added, “Following a strong third quarter, we remain confident about meeting our full year 2026 outlook of €255 – 265 million of Gaming Win and €20 – 25 million of Adjusted EBITDA. Our third quarter benefited from the final stages of the World Cup in July and from favorable exchange rates, and against a strong fourth quarter last year, we expect growth in the coming months to be more in line with our underlying trends.”

Recent Events

Official Betting Partner of the NFL in Mexico

• On September 10, 2026, Codere Online announced a multi-year agreement to become Official Betting Partner of the NFL in Mexico, strengthening its premium brand positioning in one of its largest and most strategically important markets.
• The agreement includes sponsorship of the 2026 NFL Mexico City Game, to be held in Mexico City on November 22, 2026, and of Super Bowl LXI, to be held in Los Angeles in February 2027.
• It also provides a year-round platform for customer engagement, including hospitality programs, VIP experiences, activations across multiple cities in Mexico and official NFL merchandise opportunities.

Transition from Net Gaming Revenue to Gaming Win

• Beginning this quarter, Codere Online reports Gaming Win as a key operating metric in place of the measure previously presented as “Net Gaming Revenue”. Gaming Win is a key operating metric that measures the cash amount we retain from our customers’ wagering activity: amounts staked by customers on settled sports betting and casino wagers, less prizes and promotional credits paid to customers, before gaming taxes, value added taxes, other levies and all other costs and adjustments, as compiled by our gaming platforms and translated into euros at average monthly exchange rates (as applicable).
• Historical amounts previously reported as “Net Gaming Revenue” are unchanged and Codere Online’s FY 2026 outlook is reiterated on the same basis by reference to Gaming Win.
• Gaming Win is not a measure of Revenue and should not be considered an alternative to Revenue or any other financial measure determined in accordance with IFRS.

Conference Call Information

Codere Online’s management will host a conference call to discuss the results and provide a business update at 8:30 am US Eastern Time today, November 12, 2026. Access links to the audio webcast and presentation will be accessible on Codere Online’s website at www.codereonline.com. A recording of the webcast will also be available following the conference call.

Reconciliation of Net Income (IFRS) to Adj. EBITDA (non-IFRS)⁴

	Quarter ended September 30				Nine months ended September 30
Figures in EUR mm	2025	2026	Chg.		2025	2026	Chg.
Net Income (Loss)	1.4	5.5	4.2		(1.7)	11.1	12.8
(+/-) Provision for Corporate Income Tax	0.6	0.8	0.2		1.8	2.1	0.3
(+/-) Interest Expense / (Income)	1.4	(0.3)	(1.7)		4.4	(2.9)	(7.4)
(+/-) Var. In Fair Value of Public Warrants	(0.4)	(3.4)	(3.0)		1.5	(2.3)	(3.8)
(+) D&A	0.2	0.2	0.0		0.5	0.5	0.1
EBITDA	3.2	2.9	(0.3)		6.5	8.5	2.0
(+) Employee LTIP Expense	(0.2)	1.4	1.5		(0.5)	7.6	8.1
(+/-) Other Adjustments	(0.1)	0.0	0.1		(0.0)	0.0	0.0
Adj. EBITDA (Pre Non-Recurring Items)	2.9	4.2	1.3		6.0	16.1	10.1
(+) Non-Recurring Items	0.0	0.0	0.0		1.1	0.0	(1.1)
Adj. EBITDA	2.9	4.2	1.3		7.1	16.1	9.0

About Codere Online 

Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online, launched in 2014 as part of the renowned casino operator Codere Group, offers online sports betting and online casino through its state-of-the art website and mobile applications. Codere Online currently operates in its core markets of Spain, Mexico, Colombia, Panama and Argentina; this online business is complemented by Codere Group’s physical presence in Spain and throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence.

About Codere Group
Codere Group is a multinational group dedicated to entertainment and leisure. It is a leading player in the private gaming industry, with four decades of experience and with presence in seven countries in Europe (Spain and Italy) and Latin America (Argentina, Colombia, Mexico, Panama, and Uruguay).

Note on Rounding
Due to rounding, numbers presented in this document may not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.

Forward-Looking Statements
This document contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the expectations, beliefs, intentions or strategies of Codere Online Luxembourg, S.A. and its subsidiaries (collectively, “Codere Online”) regarding the future. Words such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but are not the only means of doing so. Forward-looking statements in this document include, among others, statements regarding Codere Online’s outlook, expected growth, financial performance, strategy and operations.

These statements are based on current expectations, forecasts and assumptions as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially. These include, among others: (i) changes in laws, regulations and taxes applicable to online gaming; (ii) volatility in sports betting results and in the outcome of sporting events; (iii) fluctuations in exchange rates, particularly of Latin American currencies against the euro; (iv) competition and changes in the gaming industry; (v) Codere Online’s ability to execute its business plans and manage its growth; (vi) its reliance on third-party providers, including the Codere Group; (vii) its ability to obtain and maintain gaming licenses; (viii) data protection and cybersecurity risks; and (ix) political, economic and geopolitical conditions in the markets in which it operates. Additional risks are described in Codere Online’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 20-F. Codere Online’s outlook has not been audited or reviewed by its independent auditors and should not be regarded as a representation that the results will be achieved. Codere Online undertakes no obligation to update any forward-looking statement, except as required by applicable law. All forward-looking statements attributable to Codere Online are expressly qualified in their entirety by these cautionary statements.

Key Operating Metrics
This document includes certain key operating metrics, such as Gaming Win and average monthly active players, which management uses to manage and assess the performance of the business. Gaming Win measures the cash amount we retain from our customers’ wagering activity: amounts staked by customers on settled sports betting and casino wagers, less prizes and promotional credits paid to customers, before gaming taxes, value added taxes, other levies and all other costs and adjustments, as compiled by our gaming platforms and translated into euros at average monthly exchange rates (as applicable). We use Gaming Win for budgeting and planning, monthly management and Board reporting, and assessing performance by market and product. Codere Online believes it is useful to investors because the taxes applicable to online gaming differ among our markets, and Gaming Win allows activity to be compared on a consistent basis. Gaming Win replaces the measure previously presented as “Net Gaming Revenue”, and historical amounts are unchanged. Gaming Win is not a measure of revenue and should not be considered an alternative to revenue or any other IFRS measure. These metrics may not be comparable to similarly titled measures used by other companies.

Financial Information and Non-IFRS Financial Measures
Codere Online’s financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). This document includes certain financial measures not presented in accordance with IFRS, such as Adjusted EBITDA. Codere Online believes these measures are useful to investors in evaluating its operating results and trends, but they are subject to limitations, may exclude items that are significant to understanding its financial results, and may not be comparable to similarly titled measures used by other companies. They should not be considered in isolation or as an alternative to revenue, net income, cash flows from operations or any other measure determined in accordance with IFRS. Reconciliations to the most directly comparable IFRS measures are included in this document. Codere Online does not provide a reconciliation of forward-looking Adjusted EBITDA to net income because it cannot predict, without unreasonable effort, certain items that would be required, such as finance results, foreign exchange effects and income taxes, which could be material.

Preliminary Information
The financial information and other data in this document are preliminary, unaudited and subject to change, and no independent registered public accounting firm has audited, reviewed or expressed any form of assurance on them. Adjustments, which may be material, may be identified as this information is finalized. This information is not a substitute for full financial statements prepared in accordance with IFRS, may differ from actual results and is not necessarily indicative of results for any future period.

Trademarks
This document contains trademarks and trade names of Codere Online and of other companies, including the National Football League, which are the property of their respective owners.

Contacts:

Investors and Media
Guillermo Lancha
Director, Investor Relations and Communications
Guillermo.Lancha@codereonline.com

(+34) 628.928.152

---

1 Gaming Win is a key operating metric that measures the cash amount we retain from customers’ wagering activity, as compiled by our gaming platforms. It replaces the measure previously presented as “Net Gaming Revenue”; historical amounts are unchanged. See “Key Operating Metrics” below.

2 Adjusted EBITDA is a non-IFRS measure; please see reconciliation of Net Income to Adjusted EBITDA to at the end of the report. The Adjusted EBITDA outlook is a forward-looking non-IFRS measure; please see important disclaimers at the end of the report.
3 See “Preliminary Information” below.

4 Interest includes realized foreign exchange results and the monetary impact of IAS 29 in Argentina. Other adjustments mainly reverse the impact of IAS 29 on operating results in Argentina and, from 2026, include shares withheld for taxes under the employee long-term incentive plan. Non-recurring items in 9M 2025 relate to excess audit-related fees. For further detail, see page 21 of our Q3 2026 Earnings Presentation, furnished on Form 6-K on November 12, 2026.

• Fully enrolled Cohorts 1 and 2 of AX-0811 Phase 1 trial; initial target engagement data expected in early January 2027
• Full AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, and new AX-0811 preclinical proof-of-concept data to be presented in December 2026
• Multiple clinical milestones expected in H1 of 2027, including initiation of pediatric biliary atresia IIT, initial AX-0422 patient data in MPS I Hurler syndrome, and advancement of AX-2911 into the clinic for MASH IIT
• Ended Q3 2026 with € 103 million cash and cash equivalents, supporting runway into mid-2028

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update.

“Having established the first clinical validation of our Axiomer RNA editing platform, we are now expanding our pipeline on that foundation through several other programs that are entering clinical development,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “The Phase 1 study of AX-0811 has now fully enrolled its first two cohorts. AX-0811 is our next-generation editing oligonucleotide targeting NTCP for cholestatic diseases, including biliary atresia. We also strengthened our AI capabilities through the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to our Board as a strategic AI advisor.”

De Boer continued, “We expect to report initial AX-0811 data in early January 2027 and look forward to presenting the full AX-0810 Phase 1 dataset, including Cohort 3, in December 2026. We expect these data to be followed by a series of additional clinical milestones across our pipeline in the first half of 2027, including initiation of our biliary atresia clinical program, initial patient data from AX-0422 in MPS I Hurler syndrome, and advancement of AX-2911 for MASH into the clinic. Across these programs, our focus remains on developing RNA editing therapies that can make a meaningful difference for patients and their families.”

Recent Progress and Anticipated Upcoming Events

Clinical Development Progress with NTCP Programs

Following the positive AX-0810 Phase 1 target engagement data reported in June 2026, ProQR expects to present the full dataset, including Cohort 3 and 12-week follow up, at the Nature Conferences RNA at the Bench and Bedside V meeting in December 2026.

In September 2026, ProQR announced the dosing of the first participant in the Phase 1 clinical trial of AX-0811, the Company’s next-generation editing oligonucleotide targeting NTCP, which was identified through ProQR’s AI-enabled discovery engine. The first two cohorts of healthy volunteers are now fully enrolled, with initial AX-0811 Phase 1 target engagement data expected in early January 2027. The study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamic effects via biomarker-based target engagement. AX-0811 preclinical data demonstrate greater potency and a longer half-life compared with AX-0810, with the potential for lower dose levels and less frequent dosing in the clinic.

In September 2026, the Company hosted a virtual educational event focused on NTCP modulation in biliary atresia through liver-targeted RNA editing. The event featured ProQR management and Professor Gideon Hirschfield of the Toronto Centre for Liver Disease and provided an overview of bile acid biology, NTCP modulation, translational rationale and clinical development strategy for RNA editing NTCP modulation in biliary atresia. The event outlined the framework for evaluating upcoming AX-0811 Phase 1 target engagement data:

• TUDCA is expected to be the most sensitive measure for comparing pharmacodynamic effects,
• Conjugated bile acid profile will be informative for assessing translation into the disease setting, and
• Total bile acids in serum provides an additional supportive measure of target engagement.

Based on preclinical data, ProQR expects AX-0811 to outperform AX-0810 across all three biomarkers in equivalent cohorts.

ProQR is also continuing preparations for an investigator-initiated trial (IIT) in pediatric biliary atresia in China, with initial clinical data expected in the first half of 2027.

Conference Presentations

In November 2026, ProQR participated in TIDES Europe and The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), where presentations highlighted previously disclosed AX-0810 clinical findings and preclinical data for AX-0811.

Strengthening AI and Data Capabilities

In September 2026, ProQR appointed Chris Hart, PhD, as Chief Data and AI Officer. Dr. Hart most recently served as Vice President of Data Science and AI/ML for Genetic Medicines at Eli Lilly and Company and has more than 15 years of experience applying AI/ML to oligonucleotide therapeutics. ProQR also announced in September that Thomas Wolf, PhD, co-founder and Chief Scientific Officer of Hugging Face, has joined ProQR’s Board of Directors as a strategic AI advisor.

Upcoming anticipated milestones

NTCP programs

• AX-0810 data from the 9 mg/kg cohort and 12-week follow up from the ongoing Phase 1 study and new preclinical data for AX-0811 expected in December 2026
• AX-0811 initial target engagement data from Cohorts 1 and 2 in healthy volunteers expected in early January 2027
• IIT in pediatric biliary atresia in China, with initiation and initial data targeted for the first half of 2027
• Potentially registration-enabling Phase 2 program, subject to regulatory interactions, expected to start in mid-2027 with first interim analysis data expected by mid-2028

Other pipeline candidates

• AX-0422 for MPS I Hurler Syndrome (IDUA) CTA filing for a first-in-patient study anticipated in early 2027 and initial data expected in the first half of 2027
• AX-2911 (PNPLA3) FIH IIT in China expected in the first half of 2027

Partnership

• Continue to execute on Lilly collaboration, with potential data updates and milestone payments

Financial Highlights

At September 30, 2026, ProQR held cash and cash equivalents of approximately € 103.0 million, compared to € 92.4 million at December 31, 2025.

Net cash used in operating activities during the third quarter ended September 30, 2026 was € 13.6 million, compared to € 12.2 million used for the same period in 2025.

Research and development (R&D) costs for the quarter ended September 30, 2026 were € 14.3 million, compared to € 11.1 million for the same period last year.

General and administrative costs for the quarter ended September 30, 2026 were € 4.0 million, compared to € 3.1 million for the same period in 2025.

Net loss for the quarter ended September 30, 2026 was € 12.4 million, or € 0.09 per diluted share, compared to € 11.0 million, or € 0.10 per diluted share, for the same period in 2025.

For further financial information for the period ended September 30, 2026, please refer to our Q3 financial report filing available on our website, www.proqr.com under Financials and Filings.

About Axiomer^™

ProQR is pioneering a next-generation RNA base editing technology called Axiomer^™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer^™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer^™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is a clinical-stage company dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer^™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, technology, strategy, preclinical and clinical model data; our initial pipeline targets and the upcoming strategic priorities and milestones related thereto; the continued advancement of our lead development pipeline programs, including ongoing and planned clinical trials; the ongoing Phase 1 clinical study of AX-0810 targeting NTCP for cholestatic diseases, including the timing and presentation of the full Phase 1 dataset, including Cohort 3 and 12-week follow-up data, in December 2026 at the Nature Conferences RNA at the Bench and Bedside V meeting and the presentation of new preclinical data for AX-0811; our expectations regarding the safety, tolerability, target engagement and potential therapeutic benefits of AX-0810; our ability to collaborate with investigators to initiate, conduct and recruit for an IIT of our NTCP program in China in pediatric participants with biliary atresia and to generate meaningful data therefrom, including the anticipated timing of initial data readout in the first half of 2027; the anticipated initiation of our potentially registration-enabling Phase 2 program in mid-2027 with first interim analysis data expected by mid-2028, subject to regulatory interactions; our pipeline targets, including the ongoing Phase 1 clinical trial of AX-0811 in healthy volunteers; our ability to continue to enroll and complete the ongoing Phase 1 clinical trial for AX-0811 and the anticipated timing of initial data readout expected in early January 2027; the anticipated first-in-patient study of AX-0422 targeting IDUA for MPS I Hurler syndrome, with a CTA filing expected in early 2027 and anticipated initial clinical data readout in the first half of 2027; the anticipated IIT in China of AX-2911 targeting PNPLA3 for MASH in the first half of 2027; our expectations regarding clinical updates across multiple programs in 2026 and 2027; the potential design, initiation and timing of a potentially registration-enabling Phase 2 program for the NTCP franchise, subject to regulatory interactions; the therapeutic potential and development timeline regarding AX-0810, AX-0811, AX-0422, and AX-2911; our participation at upcoming scientific conferences; the continued development and advancement of our Axiomer platform and our AI-enabled discovery engine, and the anticipated benefits of our AI and data capabilities; the therapeutic potential of our Axiomer RNA editing oligonucleotides and product candidates; the timing, progress and results of our preclinical studies and other development and pipeline activities, including the release of data related thereto; our patent estate, including its anticipated strength and our continued investment in it, as well as the timing of our clinical development; the potential of our technologies and product candidates; the collaboration with Lilly and the intended benefits thereof, including timing for data updates, and potential milestones; and our financial position and expected cash runway to fund our operations into mid-2028. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, risks and uncertainties associated with conducting IITs in China, including evolving regulatory requirements, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted due to shortage and pressure on supply chains and logistics in the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and our reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, inflationary pressures, fluctuating interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com

PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Financial Position

		September 30,		December 31,
		2026		2025
		€1,000		€1,000
Assets
Property, plant and equipment		11,046		12,630
Investments in financial assets		—		—
Non-current assets		11,046		12,630
Cash and cash equivalents		102,986		92,413
Trade and other receivables		4,285		6,800
Other taxes		781		913
Current assets		108,052		100,126
Total assets		119,098		112,756
Equity and liabilities
Equity
Equity attributable to owners of the Company		68,184		49,374
Total equity		68,184		49,374
Liabilities
Borrowings		—		—
Lease liabilities		7,790		9,547
Deferred income		9,422		21,394
Non-current liabilities		17,212		30,941
Borrowings		5,090		4,872
Lease liabilities		1,692		1,545
Derivative financial instruments		183		234
Trade payables		2,564		298
Social securities and other taxes		102		—
Deferred income		13,578		17,552
Other current liabilities		10,493		7,940
Current liabilities		33,702		32,441
Total liabilities		50,914		63,382
Total equity and liabilities		119,098		112,756

PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
(€ in thousands, except share and per share data)

		Three month period				Nine month period
		ended September 30,				ended September 30,
		2026		2025		2026		2025
		€1,000		€1,000		€1,000		€1,000
Revenue		5,155		2,882		15,947		11,218
Other income		—		33		—		413
Research and development costs		(14,323)		(11,080)		(38,820)		(34,811)
General and administrative costs		(3,967)		(3,119)		(12,733)		(11,169)
Total operating costs		(18,290)		(14,199)		(51,553)		(45,980)
Operating result		(13,135)		(11,284)		(35,606)		(34,349)
Finance income and expense		658		280		1,022		927
Results related to financial liabilities measured at fair value through profit or loss		30		(2)		51		176
Result before corporate income taxes		(12,447)		(11,006)		(34,533)		(33,246)
Income taxes		—		—		(25)		(18)
Result for the period		(12,447)		(11,006)		(34,558)		(33,264)
Other comprehensive income (foreign exchange differences on foreign operation)		28		(23)		255		(1,076)
Total comprehensive income		(12,419)		(11,029)		(34,303)		(34,340)
Result attributable to
Owners of the Company		(12,447)		(11,006)		(34,558)		(33,264)
Total comprehensive income attributable to
Owners of the Company		(12,419)		(11,029)		(34,303)		(34,340)
Share information
Weighted average number of shares outstanding1		141,231,466		105,344,996		118,982,158		105,328,752
Earnings per share attributable to owners of the Company (Euro per share)
Basic loss per share1		(0.09)		(0.10)		(0.29)		(0.32)
Diluted loss per share1		(0.09)		(0.10)		(0.29)		(0.32)

1. For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal.

PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Changes in Equity

		Attributable to owners of the Company
		Number of shares		Share Capital		Share Premium		Equity settled Employee Benefit Reserve		Translation Reserve		Accumulated Deficit		Total Equity
				€1,000		€1,000		€1,000		€1,000		€1,000		€1,000
Balance at January 1, 2025		107,710,916		4,308		483,812		26,248		1,350		(427,158)		88,560
Result for the period		—		—		—		—		—		(33,264)		(33,264)
Other comprehensive income		—		—		—		—		(1,076)		—		(1,076)
Recognition of share-based payments		—		—		—		2,784		—		—		2,784
Treasury shares transferred		(132,665)		—		—		—		—		—		—
Share options lapsed		—		—		—		(1,532)		—		1,532		—
Share options exercised / RSUs vested		132,665		—		67		(184)		—		184		67
Balance at September 30, 2025		107,710,916		4,308		483,879		27,316		274		(458,706)		57,071
Balance at January 1, 2026		107,710,916		4,308		483,881		28,426		265		(467,506)		49,374
Result for the period		—		—		—		—		—		(34,558)		(34,558)
Other comprehensive income		—		—		—		—		255		—		255
Recognition of share-based payments		—		—		—		3,955		—		—		3,955
Issuance of ordinary shares		35,755,393		1,430		47,478		—		—		—		48,908
Treasury shares transferred		(212,754)		—		—		—		—		—		—
Share options lapsed		—		—		—		(2,428)		—		2,428		—
Share options exercised / RSUs vested		212,754		—		250		(298)		—		298		250
Balance at September 30, 2026		143,466,309		5,738		531,609		29,655		520		(499,338)		68,184

PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Cash Flows

		Three month period				Nine month period
		ended September 30,				ended September 30,
		2026		2025		2026		2025
		€1,000		€1,000		€1,000		€1,000
Cash flows from operating activities
Net result		(12,447)		(11,006)		(34,558)		(33,264)
Adjustments for:
— Other income		—		(33)		—		(413)
— Depreciation		777		671		2,178		2,024
— Share-based compensation		1,169		1,117		3,955		2,784
— Financial income and expenses		(706)		(280)		(1,075)		(927)
— Results related to financial liabilities measured at fair value through profit or loss		(30)		2		(51)		(176)
— Income tax expenses		—		—		25		18
Changes in working capital		(2,961)		(3,074)		(8,606)		(10,974)
Cash used in operations		(14,198)		(12,603)		(38,132)		(40,928)
Corporate income tax paid		—		—		(25)		(18)
Interest received		740		519		1,466		1,924
Interest paid		(128)		(151)		(310)		(412)
Net cash used in operating activities		(13,586)		(12,235)		(37,001)		(39,434)
Cash flow from investing activities
Purchases of property, plant and equipment		(354)		(169)		(809)		(494)
Net cash used in investing activities		(354)		(169)		(809)		(494)
Cash flows from financing activities
Proceeds from issuance of shares, net		(293)		—		48,908		—
Proceeds from exercise of share options		250		—		250		67
Repayment of lease liability		(300)		(444)		(1,225)		(1,304)
Net cash (used in) / generated by financing activities		(343)		(444)		47,933		(1,237)
Net (decrease) / increase in cash and cash equivalents		(14,283)		(12,848)		10,123		(41,165)
Currency effect cash and cash equivalents		144		(34)		450		(1,360)
Cash and cash equivalents, at beginning of the period		117,125		119,765		92,413		149,408
Cash and cash equivalents at the end of the period		102,986		106,883		102,986		106,883

CHICAGO, Nov. 12, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced that Chris Cartwright, President and CEO, will present at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026. The presentation is scheduled to begin at 9:20 a.m. CT (10:20 a.m. ET). A live webcast of the presentation will be made available on the TransUnion Investor Relations website at http://www.transunion.com/tru. A replay will also be available on the company’s website following the conclusion of the presentation.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

http://www.transunion.com/business

Contact Greg Bardi, Investor Relations

E-mail gregory.bardi@transunion.com

Telephone 312-985-2860

• Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027
• Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks
• Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027
• Strong financial position with cash and cash equivalents of €283 million as of September 30, 2026

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update.

“The successful readout of the pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks was a major milestone for Pharvaris. If approved, deucrictibant could potentially address unmet needs across both on-demand and long-term prophylaxis of bradykinin-mediated angioedema attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Results of multiple data analyses from deucrictibant studies, including from CHAPTER-3, will be presented this weekend at the ACAAI Annual Scientific Meeting, providing the Pharvaris team with an excellent opportunity to engage with the scientific community of experts in the field of allergy and immunology. Additionally, our team is preparing for our potential first commercial launch and is well on its way to building an experienced commercial team.”

Recent Business Updates
Development Pipeline

• Review of marketing authorization applications of deucrictibant immediate-release (IR) capsule as a potential on-demand treatment of HAE attacks underway by regulatory authorities. The company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is under review by the U.S. Food and Drug Administration (FDA), with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027. The marketing authorization application (MAA) for deucrictibant IR is under formal review by the European Medicines Agency (EMA) under the centralized procedure.
• Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027. CREAATE is a global, pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. In part 1 of CREAATE, 24 participants were enrolled and randomized to receive either deucrictibant extended-release (XR) tablet (40 mg) or placebo once daily for the prophylactic treatment of AAE-C1INH attacks. Pharvaris expects to announce topline data from part 1 of CREAATE in the first quarter of 2027.
• Enrollment in part 2 of CREAATE progressing as planned. In part 2 of CREAATE, participants treat two AAE-C1INH attacks in a cross-over fashion, one attack with deucrictibant IR and one with placebo according to a randomized treatment sequence. Part 3 of CREAATE is the open-label extension portion of the study assessing the long-term safety and effectiveness of deucrictibant IR for on-demand treatment.
• CHAPTER-3 (NCT06669754) met the primary endpoint and all secondary efficacy endpoints with statistical significance. Outcomes from CHAPTER-3, a pivotal global Phase 3 study of investigational deucrictibant XR for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE, confirmed the potential deucrictibant’s differentiated profile for the prophylaxis of HAE attacks. Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001); further post-hoc analysis in participants with HAE Type 1 or Type 2 showed the mean monthly attack rate was 87% lower in the deucrictibant XR group compared to placebo. Administration of deucrictibant XR resulted in early-onset protection within the first week, which was then sustained through the 24 weeks of study treatment. Robust reductions in attack rate from baseline and increases in the percentage of attack-free participants were observed in the deucrictibant-treated group. Deucrictibant XR was generally well tolerated with most treatment-emergent adverse events being mild or moderate.
• Filing of U.S. NDA of deucrictibant for the prophylaxis of AE-BK attacks anticipated 1H2027. Pharvaris is preparing the dossier for deucrictibant XR’s NDA filing. The data from CHAPTER-3, CHAPTER-4 (NCT06679881), and part 1 of CREAATE will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027.
• RAPIDe-3 study results highlighting deucrictibant’s rapid and sustained efficacy in treating HAE attacks published in The Lancet. RAPIDe-3, a pivotal global Phase 3 study evaluating orally administered deucrictibant IR for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), confirmed the potential of deucrictibant’s differentiated profile for the on-demand treatment of HAE attacks. The primary endpoint, median time to onset of symptom relief, was achieved in 1.28 hours, significantly faster versus placebo (p<0.0001). Deucrictibant IR achieved End of Progression™ (EoP) of attack symptoms and complete symptom resolution significantly faster than placebo, with most attacks being adequately controlled with a single capsule. Deucrictibant IR was well tolerated with no safety signals observed.
• Real-world analysis highlighting HAE disease experience and gaps in treatment satisfaction published in Advances in Therapy. Insights evaluating how HAE is managed in clinical practice highlight opportunities for further advancement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options.

Upcoming Investor Events

• 9th Annual Evercore Healthcare Conference. Miami, FL, Nov. 30-Dec. 2, 2026.
  • Format: Fireside Chat
    Date, time: Wednesday, Dec. 2, 10:00 a.m. EST

Live audio webcasts of the presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replays will be available on Pharvaris’ website for 30 days following the presentation.

Financials
Third Quarter 2026 Financial Results

• Liquidity Position. Cash and cash equivalents were €283 million as of September 30, 2026, compared to €292 million for December 31, 2025.
• Research and Development (R&D) Expenses. R&D expenses were €32.4 million for the quarter ended September 30, 2026, compared to €29.8 million for the quarter ended September 30, 2025.
• General and Administrative (G&A) Expenses. G&A expenses were €17.7 million for the quarter ended September 30, 2026, compared to €9.8 million for the quarter ended September 30, 2025.
• Loss for the quarter. Loss for the third quarter was €47.4 million, resulting in basic and diluted loss per share of €0.67 for the quarter ended September 30, 2026, compared to €37.1 million, or basic and diluted loss per share of €0.60, for the quarter ended September 30, 2025.

Note on International Financial Reporting Standards (IFRS)
Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency.

About Deucrictibant
Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Forward Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA and MAA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, CHAPTER-1, and CHAPTER-3 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.

Contact 
Maggie Beller 
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets, today announced financial results for the three and nine months ended September 30, 2026.

“This was a record quarter for Figure, highlighted by another consecutive quarter of over 100% volume growth and the rapid expansion of our capital-light marketplace, with Figure Connect now making up 72% of our standalone volume. The successful acquisition of Kiavi adds diversified new asset classes to our ecosystem and supercharges our marketplace growth. As we work towards expanding the reach of our technology and bringing large institutional buyers onto our blockchain rails, we are rapidly scaling the future of capital markets.”

– Michael Tannenbaum, CEO

Q3 2026 Quarterly Financial Highlights

• Loan Marketplace volume was $5.8 billion in the quarter, a 135% increase from the prior year including $677 million of volume contributed by Kiavi, which was acquired effective September 1, 2026. Total Loan Marketplace Volume included Figure Connect Volume of $4.3 billion.
• Net revenue was $287 million, an increase of 84% year-over-year. Adjusted Net Revenue was $283 million, an increase of 83% from the third quarter of 2025.
• Net income remained flat at $89 million; net income margin was 31%, a decrease of 26 percentage points year-over-year.
  • Q3 2025 net income included a one-time tax benefit of $31 million primarily due to the recognition of deferred tax assets following the recombination of FT Intermediate, Inc. and Figure Markets Holdings, Inc.
• Adjusted EBITDA increased 91% year-over-year to $164 million; Adjusted EBITDA margin reached 58%, an increase of 3 percentage points year-over-year.
• Cash and cash equivalents, excluding restricted cash, totaled $1.6 billion, an increase of $392 million, or 33% compared to December 31, 2025.
• Loans held for sale totaled $644 million, an increase of $240 million, or 59%, compared to December 31, 2025.

Financial Highlights

$ in thousands, except per share or otherwise noted		Q3				Q3				9M YTD				9M YTD				Q3			9M YTD
(Unaudited)			2026				2025				2026				2025			YoY %			YoY%
GAAP Results:
Net Revenue		$	287,122			$	156,365			$	679,717			$	346,952			84	%		96	%
Net Income			89,315				89,822				221,798				119,203			(1	)%		86	%
Net Income margin			31	%			57	%			33	%			34	%		-26  p.p.			-2  p.p.
Earnings per Share – Basic		$	0.40			$	0.42			$	1.00			$	0.48			(5	)%		108	%
Earnings per Share – Diluted			0.36				0.34				0.90				0.38			6	%		137	%
Non-GAAP Results(1):
Adjusted Net Revenue		$	283,347			$	155,115			$	668,635			$	353,992			83	%		89	%
Adjusted EBITDA			163,564				85,443				365,639				166,653			91	%		119	%
Adjusted EBITDA margin			58	%			55	%			55	%			47	%		+3  p.p.			+8  p.p.

⁽¹⁾ _{See “Non-GAAP Financial Measures” at the end of this earnings release for details regarding these measures, including reconciliations of the Non-GAAP Financial Measures to their most directly comparable GAAP measures.}

Selected Metrics

$ in millions unless noted		Q3			Q3			9M YTD			9M YTD			Q3			9M YTD
(Unaudited)		2026			2025			2026			2025			YoY %			YoY%
Loan Marketplace Volume		5,796			2,469			12,957			5,673			135	%		128	%
Figure Connect Volume		4,259			1,131			8,644			2,376			276	%		264	%
Gross Take Rate		3.9	%		5.2	%		4.1	%		4.9	%		-1.3  p.p.			-0.8  p.p.
Net Take Rate		3.5	%		4.4	%		3.6	%		4.1	%		-0.9  p.p.			-0.5  p.p.

$ in millions unless noted		As of
(Unaudited)		September 30, 2026			December 31, 2025
$YLDS in Circulation		$	504		$	328
Prime (formerly Democratized Prime):
Matched Offers			588			206
Borrower Demand			600			246
Available Lender Supply			825			213

Recent Business Highlights

• Figure Connect reached 72% of standalone Loan Marketplace volume in the quarter, reflecting the rapid transition toward our capital light model.
• Expanded our partner base to 612 standalone partners and 894 including Kiavi, including over 20 active depository partners.
• Small/Medium Business (“SMB”) loan originations achieved a major milestone, crossing a $500 million run-rate volume supported by over 150 active partners.
• Deployed a new agentic Loan Officer Assistant in partnership with Sierra, which has processed roughly $260 million in funded loans and driven a 29% increase in funded dollars per loan approval.
• Scaled blockchain-based settlement efficiency, with 28 participants now utilizing the YLDS stablecoin for marketplace transactions.
• Completed the acquisition of Kiavi on September 1, adding $8 billion in annual run-rate volume and expanding Figure into the Residential Transition Loan (“RTL”) and Debt Service Coverage Ratio (“DSCR”) markets. Actioned $30 million in initial cost synergies since closing the transaction.
• Board of Directors authorized a $200 million increase to the share repurchase program, bringing total authorization to $400 million.

Operating Outlook

The guidance for Q4 2026 provided below constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding “Forward-looking Statements” in this press release.

Q4 2026 Guidance
Loan Marketplace Volume	$6.2 – $6.7 billion
Gross Take Rate	3.1% – 3.4%

Webcast Information

Figure will host a conference call and webcast at 8:30 a.m. Eastern Time, November 12, 2026 to discuss its results and outlook. A link to the live discussion and accompanying presentation will be made available on the Company’s investor relations website at https://investors.figure.com/. A replay will also be made available following the discussion at the same website.

Forward-Looking Statements Disclosure

This press release contains forward-looking statements intended to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including without limitation statements regarding our ability to realize the expected benefits of the completed Kiavi acquisition and to successfully integrate the business of Kiavi, future financial performance and guidance, including our expectations regarding our Loan Marketplace Volume and Gross Take Rate; our ability to remain profitable; our ability to maintain, expand, and enter into new relationships with partners and loan purchasers on the secondary market; our ability to broaden our network of partners; and our ability to successfully execute our business and growth strategy, including the expected benefits of our capital-light marketplace business model and its effect on our exposure to lending market conditions; marketplace volume, adoption, and liquidity, including the growth and performance of our Loan Marketplace, Figure Connect, and Prime platforms and our SMB loan products; and our blockchain ecosystem and infrastructure initiatives, including our ability to expand the adoption of our blockchain-native products and services by institutional participants, and the development and performance of our digital asset offerings and our AI-enabled tools. These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms, and similar expressions. Forward-looking statements are predictions based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements speak only as of the date of this press release.

Important factors that could cause actual results to differ materially include, among others: our history of losses and the risk that we may not maintain profitability; our reliance on HELOCs and exposure to fluctuations in the HELOC market and housing values; our ability to attract and retain borrowers, partners, and loan purchasers and to drive adoption of Figure-branded and Partner-branded channels including Figure Connect; loan performance and default rates and the effect of credit performance on access to and pricing of warehouse facilities, whole-loan sales, and securitizations; changes in interest rates and U.S. monetary policy that impact originations, funding costs, and investor demand; legal and regulatory risks affecting lending and mortgage-related activities and the evolving framework for digital assets, including potential changes in the characterization or regulation of certain digital assets and related products; dependence on key third-party providers including cloud, custodial, valuation, and data vendors and risks from outages or service disruptions; technology failures, cybersecurity incidents, or other operational disruptions; protection and enforcement of intellectual property; compliance with licensing, consumer protection, privacy, data security, and sanctions/AML laws, and shifting enforcement priorities at the federal and state levels; our ability to meet our public company reporting and internal control obligations; competition; macroeconomic and geopolitical conditions; our dual-class structure and concentrated voting control and related impacts on corporate governance; equity market volatility affecting our Class A common stock; and the other risks described in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 16, 2026, and in our other filings with the SEC.

You should read this press release and the documents we reference in it with the understanding that actual future results may differ materially from our expectations. We qualify all forward-looking statements in this press release by these cautionary statements. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances, or otherwise.

About Non-GAAP Financial Measures and Key Operating Metrics

Financial Measures

We present certain non-GAAP financial measures and key operating metrics. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures prepared in accordance with GAAP. Our determination and presentation of these metrics may differ from that of other companies. The presentation of these metrics is meant to be considered in addition to, not as a substitute for or in isolation from, our financial measures prepared in accordance with GAAP.

Key Operating Metrics

Loan Marketplace Volume

We define Loan Marketplace Volume as the total U.S. dollar equivalent value of originations of HELOCs, RTLs, DSCRs, and personal loans on our loan origination system, as well as the volume of third-party loans traded on Figure Connect. Beginning with the three months ended September 30, 2026, Loan Marketplace Volume (previously referred to as Consumer Loan Marketplace Volume) includes investor-focused loans originated on Kiavi’s platform following our acquisition of Kiavi on September 1, 2026, which contributed $677 million to Loan Marketplace Volume for the three and nine months ended September 30, 2026. Prior periods have not been recast because there is no impact to prior periods. We believe this measure is an indication of our scale and represents a potential revenue opportunity from the technology used for loan originations.

Gross Take Rate

Gross Take Rate is derived from the sum of ecosystem and technology fees, origination fees, gain on sale of loans, net and gain on servicing asset, net from our consolidated statement of operations. These items represent revenue generated from Figure-branded and Partner-branded volume. Valuation changes in fair value of mortgage servicing rights, which we believe are not indicative of operating performance, are deducted. Unlike Net Take Rate, marketing expenses in our operating expense are not deducted. This amount is divided by overall Loan Marketplace Volume for that period.

Net Take Rate

Net Take Rate is derived from the sum of ecosystem and technology fees, origination fees, gain on sale of loans, net and gain on servicing asset, net from our consolidated statement of operations. These items represent revenue generated from Figure-branded and Partner-branded volume. Valuation changes in fair value of mortgage servicing rights, which we believe are not indicative of operating performance, and marketing expenses in our operating expenses are deducted. This net amount is divided by overall Loan Marketplace Volume for that period.

YLDS In Circulation

We define YLDS in Circulation as the total U.S. dollar equivalent value of unsecured face-amount certificates solely backed by the assets of Figure Certificate Company (FCC), which is the issuer of the certificates. This is reported as an end of period outstanding balance.

Matched Offers

We define Matched Offers as the U.S. dollar equivalent value of offers matched between borrower and lenders on the Prime platform. This is reported as an end of period outstanding balance.

Borrower Demand

We define Borrower Demand as the U.S. dollar equivalent value that borrowers seek to borrow from the lending pool on the Prime platform. This is reported as an end of period outstanding balance.

Available Lender Supply

We define Lender Supply as the U.S. dollar equivalent value that lenders have made available in the lending pool on the Prime platform. This is reported as an end of period outstanding balance.

Non-GAAP Financial Measures

Adjusted Net Revenue

Adjusted Net Revenue is a non-GAAP financial measure used by our management to evaluate operating performance. Accordingly, we believe this measure provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. In addition, Adjusted Net Revenue provides a useful measure for period-to-period comparisons of our business, as it removes the effect of a non-cash, non-realized adjustment that is included in net revenue. Adjusted Net Revenue is defined as net revenue excluding the change in fair value of MSR due to model inputs and assumptions and change in fair value of marketable securities associated with changes in our estimates that management has determined are not reflective of our operating performance, and net of interest paid to holders of YLDS.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures used by our management to evaluate operating performance, generate future operating plans, and make strategic decisions, including those relating to operating expenses and the allocation of internal resources. Accordingly, we believe these measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. In addition, these measures provide useful information for period-to-period comparisons of our business, as they remove the effect of certain non-cash items, variable charges, non-recurring items, unrealized gains or losses or other similar non-cash items that are included in net income or expenses associated with the early stages of the business that are expected to ultimately terminate, pursuant to the terms of certain existing contractual arrangements or expected to continue at levels materially below the historical level, or that otherwise do not contribute directly to management’s evaluation of its operating results. Adjusted EBITDA is defined as net income excluding interest expense incurred in connection with our debt obligations other than debt associated with our funding of loans held for sale, income taxes, amortization expense, stock-based compensation expense, non-cash changes in certain financial instruments, and other items that management has determined are not reflective of our ongoing operating performance. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by adjusted net revenue. The most directly comparable GAAP measure is net income margin (calculated as net income divided by total net revenue).

Beginning with the quarter ended March 31, 2026, we excluded valuation changes in the fair value of marketable securities from Adjusted Net Revenue and Adjusted EBITDA and began presenting YLDS funding costs net within Adjusted Net Revenue. Beginning with the quarter ended June 30, 2026, we excluded acquisition-related costs from Adjusted EBITDA. Prior period amounts presented in the reconciliation table below have been recast to conform to the current presentation. Amortization expense excluded from Adjusted EBITDA includes amortization of intangible assets recognized in the Kiavi acquisition, which closed on September 1, 2026.

Management excludes period-to-period changes in the fair value of marketable securities from Adjusted Net Revenue and Adjusted EBITDA because they reflect non-cash, unrealized mark-to-market fluctuations driven by external market factors, including changes in discount rates, prepayment speeds, and credit spreads, that are not reflective of the Company’s underlying operating performance.

The Company’s economic benefit from YLDS is the 35 basis point spread it retains on outstanding balances, regardless of the total amount of YLDS in circulation. Management therefore presents YLDS-related interest expense net of associated interest income within Adjusted Net Revenue, as it believes this net spread is the most meaningful measure of the YLDS’s contribution to operating performance.

The following table presents a reconciliation of Total Net Revenue to Adjusted Net Revenue, Net Income to Adjusted EBITDA and Net Income margin to Adjusted EBITDA margin for the three and nine months ended September 30, 2026 and 2025:

$ in thousands		Three Months Ended September 30,								Nine Months Ended September 30,
(Unaudited)			2026				2025				2026				2025
Total net revenue		$	287,122			$	156,365			$	679,717			$	346,952
Adjusted for:
Change in fair value of MSRs due to model inputs and assumptions			(7,861	)			(331	)			(17,440	)			10,220
Valuation changes in fair value of marketable securities(A)			6,190				(943	)			10,853				(3,174	)
YLDS funding costs(A)			(2,104	)			24				(4,495	)			(6	)
Adjusted net revenue		$	283,347			$	155,115			$	668,635			$	353,992
Net income		$	89,315			$	89,822			$	221,798			$	119,203
Adjusted for:
Change in fair value of MSRs due to model inputs and assumptions			(7,861	)			(331	)			(17,440	)			10,220
Valuation changes in fair value of marketable securities(A)			6,190				(943	)			10,853				(3,174	)
Change in fair value of digital assets and related investments			(4,962	)			(3,745	)			889				3,546
Services exchanged for issuance of warrants			—				2,459				—				7,863
Registration costs			1,399				2,430				4,559				4,277
Acquisition-related costs(A)			15,455				—				20,131				—
Restructuring costs			2,351				689				2,379				3,672
Stock-based compensation expense			24,271				17,469				76,247				22,730
Amortization(B)			8,413				4,304				17,477				12,381
Non-funding interest expense			16,127				4,752				27,273				12,811
Income tax provision (benefit)			12,866				(31,463	)			1,473				(26,876	)
Adjusted EBITDA		$	163,564			$	85,443			$	365,639			$	166,653
Net income margin			31.1	%			57.4	%			32.6	%			34.4	%
Adjusted EBITDA margin			57.7	%			55.1	%			54.7	%			47.1	%

^(A) _{The Company added valuation changes in the fair value of marketable securities and YLDS funding costs to its definition of Adjusted Net Revenue, and valuation changes in the fair value of marketable securities to its definition of Adjusted EBITDA effective March 31, 2026. Additionally, the Company added acquisition-related costs to the definition of Adjusted EBITDA effective June 30, 2026. These adjustments have been applied retrospectively to all periods presented.}
^(B) _{Amortization expense includes amortization of intangible assets recognized in the Kiavi acquisition, which closed on September 1, 2026.}

About Figure

Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) is the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets. More than 800 partners use its loan origination system and capital marketplace. Collectively, Figure and its partners have originated over $30 billion of loans to date, among other products. The fastest growing components are Figure Connect, its credit marketplace, and Prime, Figure’s on-chain lend-borrow marketplace. Figure’s ecosystem also includes DART (Digital Asset Registry Technology) for asset custody and lien perfection, and $YLDS.

Figure is the market leader in real-world asset (RWA) tokenization. The Company has received AAA ratings from S&P and Moody’s on multiple loan securitizations, the first of its kind for blockchain finance. For more information, visit https://figure.com or follow Figure on LinkedIn.

FIGURE TECHNOLOGY SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and per share data)
		September 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents		$	1,590,346			$	1,198,141
Restricted cash			204,666				68,637
Loans held for sale, at fair value			644,266				404,337
Digital assets ($86,863 and $84,867 at fair value)			98,832				96,558
Accounts receivable, net (includes $66,947 and zero with related parties)			171,893				52,016
Other current assets (includes $24,067 and zero with related parties)			193,962				41,518
Total current assets			2,903,965				1,861,207
Loan servicing asset, at fair value			196,409				113,064
Marketable securities, at fair value			449,205				273,151
Digital assets, non-current			1,407				3,644
Deferred income taxes, net			12,035				26,037
Intangible assets, net			206,983				—
Goodwill			318,742				—
Other non-current assets			75,694				40,420
Total assets		$	4,164,440			$	2,317,523
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities (includes $18,590 and $66 to related parties)		$	101,076			$	29,501
Payables to loan owners (includes $81,295 and zero to related parties)			719,395				383,772
Debt, current ($97,986 and $100,519 at fair value)			151,958				160,959
Debt, current to related parties ($593,049 and $166,135 at fair value)			593,049				166,135
Other current liabilities			74,855				105,642
Total current liabilities			1,640,333				846,009
Debt, non-current			998,275				230,143
Lease liability, non-current			7,232				4,173
Total liabilities			2,645,840				1,080,325
Commitments and Contingencies
Stockholders’ equity:
Preferred stock — $0.0001 par value per share: 100,000,000 shares authorized, no shares issued and outstanding at September 30, 2026 and December 31, 2025			—				—
Class A common stock — $0.0001 par value per share: 1,000,000,000 shares authorized, 184,851,162 shares issued and 184,538,662 shares outstanding at September 30, 2026; 1,000,000,000 shares authorized, 178,485,407 shares issued and outstanding at December 31, 2025			18				19
Class B common stock — $0.0001 par value per share: 199,481,062 shares authorized, 38,229,313 shares issued and outstanding at September 30, 2026; 200,000,000 shares authorized, 37,893,047 shares issued and outstanding at December 31, 2025			4				4
Blockchain common stock — $0.0001 par value per share: 500,000,000 shares authorized, 2,380,904 and no shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively			—				—
Treasury stock, at cost — 312,500 shares and no shares at September 30, 2026 and December 31, 2025, respectively			(9,700	)			—
Additional paid-in capital			1,493,241				1,415,804
Retained earnings (accumulated deficit)			34,968				(186,993	)
Total Figure Technology Solutions, Inc. stockholders’ equity			1,518,531				1,228,834
Noncontrolling interests in consolidated subsidiaries			69				8,364
Total stockholders’ equity			1,518,600				1,237,198
Total liabilities and stockholders’ equity		$	4,164,440			$	2,317,523

FIGURE TECHNOLOGY SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except share and per share data)
		Three Months Ended September 30,							Nine Months Ended September 30,
			2026			2025				2026			2025
Net revenue:
Ecosystem and technology fees		$	109,783		$	35,691			$	229,954		$	79,445
Servicing fees			18,358			7,882				39,486			22,537
Interest income			29,978			13,420				72,163			36,610
Origination fees			28,192			21,415				77,668			50,142
Gain on sale of loans, net			57,753			62,618				164,681			128,722
Gain on servicing asset, net			39,440			9,332				81,400			11,502
Marketable securities income, net			1,865			5,387				9,496			17,066
Other revenue			1,753			620				4,869			928
Total net revenue			287,122			156,365				679,717			346,952
Expenses:
General and administrative			59,007			36,366				156,030			71,603
Technology and product development			20,130			15,915				51,286			49,349
Operations and processing			37,374			18,217				87,735			45,342
Sales and marketing			36,847			22,144				93,068			54,077
Interest expense			29,742			12,450				66,301			35,798
Other expense (income)			2,228			(1,445	)			3,825			2,268
Total expenses			185,328			103,647				458,245			258,437
Operating income			101,794			52,718				221,472			88,515
Other income, net			387			5,641				1,799			3,812
Income before income taxes			102,181			58,359				223,271			92,327
Income tax provision (benefit)			12,866			(31,463	)			1,473			(26,876	)
Net income			89,315			89,822				221,798			119,203
Net income attributable to noncontrolling interests in consolidated subsidiaries			—			246				92			505
Net income attributable to Figure Technology Solutions, Inc.		$	89,315		$	89,576			$	221,706		$	118,698
Net income per share of Class A, Class B, and Blockchain common stock
Basic		$	0.40		$	0.42			$	1.00		$	0.48
Diluted		$	0.36		$	0.34			$	0.90		$	0.38
Weighted-average Class A, Class B, and Blockchain common shares outstanding
Basic			224,349,649			103,571,820				220,988,969			80,896,185
Diluted			247,387,034			129,922,329				247,670,690			103,106,387